fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

MHRA (UK) approves seladelpar (Livdelzi) to treat primary biliary cholangitis – CymaBay

Written by | 12 Feb 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has  16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.

Late breaking data for Iqirvo (elafibranor) from interim analysis of Phase III ELATIVE study for Primary Biliary Cholangitis at AASLD meeting – Ipsen

Written by | 20 Nov 2024

Ipsen announced  late-breaking data for Iqirvo (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American… read more.

Iqirvo (elafibranor) receives FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis – Ipsen

Written by | 24 Jun 2024

Ipsen announced that the FDA has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid… read more.

Intercept Pharmaceuticals Inc. announces updates to Ocaliva prescribing information for primary biliary cholangitis

Written by | 29 May 2021

Intercept Pharmaceuticals, Inc. announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has been updated.The changes to the Ocaliva Prescribing Information were prompted… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.